Clinical trial XL092-002 - Stellar 002
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors
| Organ | Colon |
|---|---|
| Trial status | Trial open for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 1/1b |
| Academic trial | Non |
| Sponsor | Exelixis |
| EudraCT Identifier | 2021-004855-18 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT05176483 |
| Last update |